Erectile Dysfunction in Chronic Peritoneal Dialysis Patients: Incidence and Treatment with Sildenafil

Juergense, PH; Botev, Rossini; Wuerth, Diane; Finkelstein, SH; Smith, JD; Finkelstein, FO

doi:10.1177/089686080102100404

Cited by 18 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, sildenafil has been investigated for the treatment of ED in patients with other comorbid conditions, such as Parkinson's disease (48)(49)(50), multiple sclerosis (51,52), spina bifida (53), renal failure requiring dialysis (54)(55)(56) and organ transplant (57)(58)(59)(60)(61). The extensive data from these trials demonstrate that sildenafil is well tolerated and effective for the treatment of ED in all of these patient populations.…”

Section: Patients With Ed and Comorbiditiesmentioning

confidence: 99%

Past, present, and future: a 7-year update of Viagra® (sildenafil citrate)

Jackson¹,

Gillies²,

Osterloh³

2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

More than 30 million men are estimated to have erectile dysfunction (ED) in the United States. Worldwide, ED is estimated to affect more than 150 million men, and that number is expected to exceed 300 million men by the year 2025. The prevalence of ED ranges from 7% in men aged 18-29 years to 85% in men aged 76-85 years. In addition, a recent report showed that 68% of patients with ED aged 18 years and older have at least one comorbid diagnosis of hypertension, hyperlipidaemia, diabetes or depression, and research suggests that ED may be an early indicator of systemic vascular disease. Viagra (sildenafil citrate), the first-in-class phosphodiesterase type 5 (PDE5) inhibitor, was introduced in 1998 for the treatment of ED. In the 7 years since its market launch, more than 750,000 physicians have prescribed sildenafil to more than 23 million men, helping establish an excellent safety and efficacy record. Clinical studies have demonstrated that sildenafil successfully treats ED of varied organic, psychogenic or mixed aetiology, and is effective in men with ED and comorbidities such as hypertension, hyperlipidaemia, diabetes or depression. Sildenafil was a breakthrough medication that addressed a previously unfulfilled medical need. The impact of sildenafil has stimulated academic, clinical and industrial research to better understand the nature of sexual function and develop better treatment and management for sexual dysfunctions such as ED. With the advent of other erectogenic therapies for the treatment of ED, this 7-year update will focus on the unique history and development of sildenafil, its current use and applications and its future directions and indications. Special emphasis is placed on the impact of sildenafil on our understanding of sexual health and on the extensive safety and efficacy data that have been amassed from numerous clinical trials.

show abstract

Section: Patients With Ed and Comorbiditiesmentioning

confidence: 99%

Past, present, and future: a 7-year update of Viagra® (sildenafil citrate)

Jackson¹,

Gillies²,

Osterloh³

2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Most of the reported adverse effects of sildenafil are considered mild and rarely result in discontinuation of treatment [5]. Sildenafil can improve the quality of life of patients with ED and various comorbid diseases, including ESRD [6–10]. In the present study, we evaluated the efficacy and safety of sildenafil in patients on haemodialysis (HD) or peritoneal dialysis (PD).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis

Yeniçerioğlu¹,

Kefi²,

Aslan³

et al. 2002

BJU International

View full text Add to dashboard Cite

Objective To assess the efficacy of sildenafil for erectile dysfunction (ED) in patients on haemodialysis (HD) or peritoneal dialysis (PD), as men with end-stage renal disease (ESRD) often have sexual dysfunction (up to 82% among those on chronic dialysis). Patients and methods Forty-one patients with ED and in ESRD participated in an open-label prospective study. Thirty patients on HD and 11 on PD were asked to complete the International Index of Erectile Function (IIEF) and Fugl-Meyer life-satisfaction scale before and after sildenafil treatment. A total score in the erectile function domain of ≤ 25 was accepted as indicating ED. All patients were started on a 25-mg dose, which was increased to 50 mg if there was no response after two trials. In addition, the overall efficacy question was used to evaluate satisfaction, and patients reported any side-effects during treatment. Results The erectile function and intercourse satisfaction domains improved significantly in both groups ( P < 0.01). After sildenafil treatment, two-thirds of those on HD (20/30) and nine of the 11 on PD recovered their erectile function. The pretreatment scores on the IIEF and four domains (except sexual desire) of those responding were significantly higher than in those not responding ( P < 0.05). The satisfaction rate on the overall efficacy question was 80% and 82% for the HD and PD groups, respectively. At least one sideeffect was seen in 17 patients (43%); one had severe hypotension in the PD group. Overall, mild headache (seven patients, 18%) and flushing (12, 30%) were reported most often. Conclusions Sildenafil is a safe and satisfactory drug for improving erectile function in patients with ESRD.Patients were satisfied whether treated by HD or PD. Pretreatment scores on the IIEF may be useful for predicting the success of treatment.

show abstract

“…Medication safety is difficult to interpret in the small studies, including ours, that have been investigated until now. Sildenafil was well tolerated in the selected dialysis patients who reported improved sexual function with no major adverse effects (8,9,(11)(12)(13)(14)(15)(20)(21)(22)(23)(24)(25)(26)(27)29). Larger studies of patients with ESRD are warranted.…”

Section: Discussionmentioning

confidence: 99%

“…A cutoff score of 21 (range 1-25) was used to define ED. ED was classified likewise into 5 validated severity levels, ranging from none (22)(23)(24)(25), mild (17)(18)(19)(20)(21), mild/moderate (12)(13)(14)(15)(16), moderate (8-11) through severe (1-7).…”

Section: Sexual Function: Iief-5mentioning

confidence: 99%

Kidney Disease Quality of Life of Japanese Dialysis Patients Who Desire Administration of Sildenafil and the Treatment of Erectile Dysfunction Using Sildenafil

et al. 2004

View full text Add to dashboard Cite

Erectile dysfunction (ED) is common among patients on dialysis therapy. In the present study, we attempted administration of sildenafil to Japanese patients undergoing dialysis. In order to diagnose ED before prescribing sildenafil, we assessed the hemodialysis patients who desired sildenafil by using the five items version of the International Index of Erectile Function (IIEF-5). In addition, the characteristics of the quality of life in Japanese hemodialysis patients who desired sildenafil were assessed using the kidney disease quality of life (KDQOL). To all 37 male subjects (mean age of 53.8 +/- 10.4 years) attending the Outpatient Hemodialysis Unit at Atsugi Clinic (Atsugi City, Japan), it was explained by their primary doctor that the treatment of ED with sildenafil was possible. As a result, 10 patients (27.0%) desired the treatment. For eight patients, ED was diagnosed by IIEF-5 prior to prescription of sildenafil. The mean IIEF-5 scores were 6.13 +/- 4.67 points. Sildenafil was prescribed to five patients (three diabetic, two non-diabetic) and sexual function was improved in three cases. The main adverse effect was found to be ventricular arrhythmia in one case. As for KDQOL, the group desiring sildenafil showed significantly high values in Dialysis Staff Encouragement and Patient Satisfaction. Among the other nine dialysis patients (five diabetic, four non-diabetic; mean age of 58.1 +/- 8.9 years) who visited the ED department of Ishida Hospital (Asahikawa City, Japan), sildenafil was effective for all non-diabetic patients (100%) and for only one diabetic patient (20%). Among all 14 patients at Atsugi Clinic and Ishida Hospital, sildenafil efficacy rates were 83.3% for non-diabetic patients and 37.5% for diabetic patients. Non-diabetic patients without the side-effects were all responders for the sildenafil treatment. The patients who relied on the dialysis staff and were more satisfied with the general treatment in the dialysis institute desired the administration of sildenafil under the present circumstances wherein the dialysis population had few experiences of sildenafil treatment. Diabetic status is thought to be a negative factor for the response of sildenafil treatment in dialysis patients.

show abstract

Erectile Dysfunction in Chronic Peritoneal Dialysis Patients: Incidence and Treatment with Sildenafil

Cited by 18 publications

References 11 publications

Past, present, and future: a 7-year update of Viagra® (sildenafil citrate)

Past, present, and future: a 7-year update of Viagra® (sildenafil citrate)

Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis

Kidney Disease Quality of Life of Japanese Dialysis Patients Who Desire Administration of Sildenafil and the Treatment of Erectile Dysfunction Using Sildenafil

Contact Info

Product

Resources

About